
TY  - JOUR
AU  - Ogaki, Shigeru
AU  - Taguchi, Kazuaki
AU  - Watanabe, Hiroshi
AU  - Ishima, Yu
AU  - Otagiri, Masaki
AU  - Maruyama, Toru
TI  - Carbon Monoxide-Bound Red Blood Cell Resuscitation Ameliorates Hepatic Injury Induced by Massive Hemorrhage and Red Blood Cell Resuscitation via Hepatic Cytochrome P450 Protection in Hemorrhagic Shock Rats
JO  - Journal of Pharmaceutical Sciences
JA  - J. Pharm. Sci.
VL  - 103
IS  - 7
SN  - 0022-3549
UR  - https://doi.org/10.1002/jps.24029
DO  - doi:10.1002/jps.24029
SP  - 2199
EP  - 2206
KW  - cytochrome P450
KW  - pharmacokinetics
KW  - drug transport
KW  - hepatic metabolism
KW  - drug effects
PY  - 2014
AB  - Red blood cell (RBC) transfusions are the gold standard in cases of massive hemorrhage, but induce hepatic ischemia?reperfusion injury, a serious complication associated with hemorrhage and RBC resuscitation. Thus, the development of a novel resuscitable fluid that is not associated with hepatic ischemia?reperfusion injury would be desirable. It was reported that exogenous carbon monoxide (CO) treatment ameliorated hepatic ischemia?reperfusion injury accompanying liver transplantation. This suggests that transfusions with CO-bound RBC (CO-RBC) might protect against hepatic ischemia?reperfusion injury following massive hemorrhage and resuscitation compared with RBC resuscitation. To investigate this, we created a hemorrhagic shock model rat, followed by resuscitation with RBC and CO-RBC. Hepatic ischemia?reperfusion injury and the destruction of hepatic cytochrome P450 (CYP) were significantly ameliorated in the CO-RBC resuscitation group compared with the RBC resuscitation group. The free heme derived from the destruction of hepatic CYP was correlated with hepatic oxidation and injury, suggesting that CO-RBC was a major factor in the amelioration of hepatic ischemia?reperfusion injury induced by hemorrhage and resuscitation via hepatic CYP protection. These results indicate that CO-RBC has potential for use as a resuscitative fluid in blood transfusion and does not suffer from the limitations associated with the RBC transfusions that are currently in use. ? 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2199?2206, 2014
ER  - 

TY  - JOUR
TI  - 138th Annual Meeting American Neurological Association
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 74
IS  - S17
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.24068
DO  - doi:10.1002/ana.24068
SP  - S1
EP  - S120
PY  - 2013
ER  - 

TY  - JOUR
TI  - Pregnancy Outcome
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
JA  - BJOG: Int J Obstet Gy
VL  - 126
IS  - S1
SN  - 1470-0328
UR  - https://doi.org/10.1111/1471-0528.15636
DO  - doi:10.1111/1471-0528.15636
SP  - 115
EP  - 134
PY  - 2019
ER  - 

TY  - JOUR
AU  - Custers, José A.E.
AU  - Kwakkenbos, Linda
AU  - van de Wal, Marieke
AU  - Prins, Judith B.
AU  - Thewes, Belinda
C8  - PON-18-0086.R1
TI  - Re-validation and screening capacity of the 6-item version of the Cancer Worry Scale
JO  - Psycho-Oncology
JA  - Psycho‐Oncology
VL  - 27
IS  - 11
SN  - 1057-9249
UR  - https://doi.org/10.1002/pon.4782
DO  - doi:10.1002/pon.4782
SP  - 2609
EP  - 2615
KW  - cancer
KW  - Cancer Worry Scale
KW  - fear of cancer recurrence
KW  - oncology
PY  - 2018
AB  - Abstract Objective Fear of cancer recurrence (FCR) is one of the major existential unmet needs of cancer survivors. Due to growing availability of evidenced-based interventions for high FCR, valid and reliable brief measures of FCR are needed. This study aimed to validate the 6-item Cancer Worry Scale (CWS) and to establish a cut-off score for high FCR. Methods Participants in this study were 1033 cancer survivors and patients recruited as part of 5 existing studies on FCR involving patients and survivors with gastro-intestinal stromal tumors, colorectal, breast, and prostate cancer. De-identified data of the CWS, Fear of Cancer Recurrence Inventory (FCRI), Impact of Event Scale, Hospital Anxiety and Depression Scale, and EORTC-QLQ-C30 were amalgamated for the analyses. Confirmatory factor analysis of the CWS was performed. Sensitivity and specificity were tested with the FCRI as gold standard. Results Results confirmed that the 6-item version of the CWS maintained good construct validity, convergent and divergent validity, and high internal consistency (α 0.90). The optimal cut-off for the 6-item CWS was 9 versus 10 using the 12 vs 13 FCRI-SF score (sensitivity 82%, specificity 83%) and the 15 vs 16 FCRI-SF score (sensitivity 88%, specificity 73%). Using the highest FCRI-SF cut-off (21 vs 22), the optimal CWS cut-off was 11 vs 12 (sensitivity 88%, specificity 81%). Conclusions The present results provide researchers and clinicians with a brief valid and reliable measure of FCR which is suitable for measuring FCR in cancer patients and survivors.
ER  - 

TY  - JOUR
TI  - Abstracts–Symposia
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 37
IS  - s2
SN  - 0145-6008
UR  - https://doi.org/10.1111/acer.12163
DO  - doi:10.1111/acer.12163
SP  - 254A
EP  - 308A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Allergy
VL  - 65
IS  - s92
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2010.02393.x
DO  - doi:10.1111/j.1398-9995.2010.02393.x
SP  - 209
EP  - 682
PY  - 2010
ER  - 

TY  - JOUR
TI  - POSTERS
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 19
IS  - s2
SN  - 0926-9959
UR  - https://doi.org/10.1111/j.1468-3083.2005.01311.x
DO  - doi:10.1111/j.1468-3083.2005.01311.x
SP  - 1
EP  - 411
PY  - 2005
ER  - 

TY  - JOUR
TI  - 43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011 Auckland, New Zealand, 28th–30th October, 2011, SIOP Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 57
IS  - 5
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.23299
DO  - doi:10.1002/pbc.23299
SP  - 705
EP  - 897
PY  - 2011
ER  - 

TY  - JOUR
TI  - Arthritis & Rheumatism, 2001 Annual Scientific Meeting Abstracts, November 10–15, 2001, San Francisco, CA
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 44
IS  - S9
SN  - 0004-3591
UR  - https://doi.org/10.1002/1529-0131(200109)44:9+<::AID-ART425>3.0.CO;2-A
DO  - doi:10.1002/1529-0131(200109)44:9+<::AID-ART425>3.0.CO;2-A
SP  - 53
EP  - 165
PY  - 2001
AB  - Abstract Scientific Abstracts 1?678
ER  - 

TY  - JOUR
TI  - Abstract
JO  - HPB
VL  - 10
IS  - S1
SN  - 1365-182X
UR  - https://doi.org/10.1080/13651820701867935
DO  - doi:10.1080/13651820701867935
SP  - 5
EP  - 226
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Neurourology and Urodynamics
JA  - Neurourol. Urodynam.
VL  - 34
IS  - S1
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.22738
DO  - doi:10.1002/nau.22738
SP  - S2
EP  - S98
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Allergy
JA  - Allergy
VL  - 68
IS  - s97
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12250
DO  - doi:10.1111/all.12250
SP  - 189
EP  - 336
PY  - 2013
ER  - 

TY  - JOUR
TI  - 60th Annual Scientific Meeting American Headache Society® June 28-July 1, 2018 San Francisco Marriott Marquis San Francisco, CA
JO  - Headache: The Journal of Head and Face Pain
JA  - Headache: The Journal of Head and Face Pain
VL  - 58
IS  - S2
SN  - 0017-8748
UR  - https://doi.org/10.1111/head.13306
DO  - doi:10.1111/head.13306
SP  - 61
EP  - 215
PY  - 2018
ER  - 

C7  - pp. 421-446
TI  - Index
SN  - 9781119316251
UR  - https://doi.org/10.1002/9781119316268.index
DO  - doi:10.1002/9781119316268.index
SP  - 421-446
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Oral Representation
JO  - HPB
JA  - HPB
VL  - 16
IS  - s2
SN  - 9781119316251
UR  - https://doi.org/10.1111/hpb.12231
DO  - doi:10.1111/hpb.12231
SP  - 258
EP  - 316
PY  - 2014
ER  - 

TY  - JOUR
TI  - Oral and Poster Presentations
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 77
IS  - S1
SN  - 9781119316251
UR  - https://doi.org/10.1002/ccd.23089
DO  - doi:10.1002/ccd.23089
SP  - S1
EP  - S156
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 23
IS  - S1
SN  - 9781119316251
UR  - https://doi.org/10.1002/pds.3701
DO  - doi:10.1002/pds.3701
SP  - 1
EP  - 497
PY  - 2014
ER  - 

TY  - JOUR
TI  - IVECCS Large Animal Abstracts (in alphabetical order of presenter)
JO  - Journal of Veterinary Emergency and Critical Care
VL  - 17
IS  - 3s1
SN  - 9781119316251
UR  - https://doi.org/10.1111/j.1476-4431.2007.00239_1.x
DO  - doi:10.1111/j.1476-4431.2007.00239_1.x
SP  - S12
EP  - S17
PY  - 2007
ER  - 

TY  - JOUR
TI  - ABSTRACTS II: III WORLD CONFERENCE on CLINICAL PHARMACOLOGY & THERAPEUTICS: Stockholm July 27–August 1, 1986
JO  - Acta Pharmacologica et Toxicologica
VL  - 59
IS  - s4
SN  - 9781119316251
UR  - https://doi.org/10.1111/j.1600-0773.1986.tb02697.x
DO  - doi:10.1111/j.1600-0773.1986.tb02697.x
SP  - 1
EP  - 342
PY  - 1986
ER  - 

TY  - JOUR
TI  - POSTER ABSTRACTS
JO  - Acta Anaesthesiologica Scandinavica
VL  - 51
IS  - s118
SN  - 9781119316251
UR  - https://doi.org/10.1111/j.1399-6576.2007.01407.x
DO  - doi:10.1111/j.1399-6576.2007.01407.x
SP  - 25
EP  - 48
PY  - 2007
ER  - 
